DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Near Add Your Location

Sorting 23 by

Infirmary Cancer Care
Mobile, AL
  • Accepting patients
Community Clinical Trials
Houston, TX
  • Accepting patients
Lifespan Rhode Island Hospital
Providence, RI
  • Not yet accepting
Winship Cancer Institute
Emory University
Atlanta, GA
  • Not yet accepting
MaineHealth Maine Medical Center
Scarborough, ME
  • Not yet accepting
John Theurer Cancer Center at Hackensack University Medical Center 
Hackensack Meridian Health
Hackensack, NJ
  • Not yet accepting
Stony Brook University Hospital
Stony Brook, NY
  • Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.